Summit Therapeu ADR SMMT

$16.75 +0.06 (0.39%)

Valuation

Market cap
13,366,300,000
Revenue TTM
$0
Net income TTM
$-1,079,590,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
5,196,100
Avg volume
6,294,898
Day's range
$16.66 – $17.32
Shares out
797,750,000
Stochastic %K
40%
Beta
-1.51
Analysts
Strong Sell
Price target
$29.06

Price

Company profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company...

Show more

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
305 203 2034
Website
https://www.smmttx.com
Address
601 Brickell Key Drive, Suite 1000, Miami, United States

Latest news

Stocktwits

TruthBroker2 Oct 4, 2:10 AM
$SMMT.
0 replies
georgenabi Oct 3, 3:34 PM
$SMMT classic accumulation. MM keeping lid on this.
0 replies
De12 Oct 3, 12:30 PM
$SMMT $30 with approval?
2 replies
De12 Oct 3, 1:30 AM
$SMMT How high does it go with approval?
1 replies
GreatDane84 Oct 2, 7:58 PM
$SMMT 43 days and counting til i can retire
2 replies
DarkMatter1 Oct 2, 7:53 PM
$SMMT looks safe to add another couple...
0 replies
MarketDegenerate Oct 2, 6:45 PM
$SMMT — Another major ivonescimab collaboration just dropped. Summit is working with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab alongside the TROP2 ADC Datroway across multiple tumor types. That’s on top of AstraZeneca’s recent $2B investment in Summit and the Nov. 14 FDA decision approaching. Ivonescimab is quickly becoming one of the more interesting oncology assets to follow.
0 replies
JeanPhi Oct 2, 6:32 PM
$SMMT people are waiting 25$ to buy lol
0 replies